Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Antiplatelet agents under research at Monsanto

March 1, 1999

Spotlight update: fibrinogen (gpIIb/IIIa) receptor antagonists

March 1, 1999

Orally active TxA2 antagonist in clinical development at Zeria

Feb. 25, 1999

Four U.S. patents provide additional protection for Corvas's rNAP program

Feb. 24, 1999

Abciximab improves microvascular perfusion after stenting in acute myocardial infarction

Feb. 24, 1999

Activase for acute management of stroke approved in Canada

Feb. 22, 1999

Astra's P2T receptor antagonists offer significant potential as novel antithrombotics

Feb. 19, 1999

Boehringer Ingelheim researches thrombin inhibitors

Feb. 19, 1999

New series of anticoagulants for oral administration developed at Lilly

Feb. 18, 1999

Another European market opens up to desirudin

Feb. 18, 1999

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...